The Growing Value of Digital Health in the United Kingdom

Evidence and Impact on Human Health and the Healthcare System

Institute Report

November 7, 2017
The Growing Value of Digital Health in the United Kingdom

Report Summary

This report on Digital Health examines trends in three areas — innovation, evidence and adoption — to assess whether these new tools are positioned to have a fundamental impact on patient care specific to the U.K. healthcare system. 

The impact of Digital Health on patient care is accelerating with the increasing adoption of mobile health apps and wearable sensors. Health-related mobile applications available to consumers now surpass 318,000 — nearly double the number available just two years ago.  This rapid app expansion, coupled with more than 340 consumer wearable devices on the market worldwide, provide evidence of Digital Health’s accelerating innovation. At this time, there is at least one high-quality app for each step of the patient journey. While the majority of mobile health apps available are general wellness apps, the number of health condition management apps—those often associated with patient care—are increasing at a faster rate, and now represent 40 percent of all health related apps.

The overall body of clinical evidence on app efficacy has grown substantially and now includes 571 published studies, enabling the identification of a list of Top Apps with increasingly robust clinical evidence.  The use of such Digital Health apps in just five patient populations where they have proven reductions in acute care utilisation (diabetes prevention, diabetes, asthma, cardiac rehabilitation and pulmonary rehabilitation) could save the U.K. healthcare system an estimated £170 million per year. This represents about 1.1% of total costs in these patient populations. If this level of savings could be extrapolated across total national health expenditure, annual cost savings of £2 billion could be achieved.

Efforts by patient care organisations to fit Digital Health tools into clinical practice has progressed, with 860 current clinical trials globally incorporating these tools. Despite progress to date, a number of barriers still exist to widespread adoption by patient care institutions, and only an intermediate level of adoption has yet occurred. A variety of industry and policy initiatives have now emerged to address these barriers and accelerate the ongoing adoption of Digital Health tools by care provider organisations.

Digital Therapeutics and the NHS
Murray Aitken and Brian Clancy will address the Digital Therapeutics in the NHS conference on April 24th 2018.